India approves $1.9 billion Agila acquisition

US generics company Mylan wins go-ahead to buy Bangalore-based injectables business from India’s Strides Arcolab.

India has approved a $1.9 billion bid for pharmaceuticals company Agila Specialties, as the country strives to dispel its image as a hostile destination for foreign investors.

Mylan, a US company that makes generic drugs, signed an agreement to buy Agila from Strides Arcolab in late February, but the acquisition stumbled after one set of regulators complained that selling to a foreign buyer could affect the availability of important cancer drugs in India.


To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition


  • 2nd Compliance Summit Southeast Asia

    17 August 2017  |  Singapore
    The 2017 Compliance Summit Southeast Asia will take an in-depth look at the key compliance considerations today with a focus on regulation and new ...